Supernus Pharmaceuticals, Inc. (LON:0LB2)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 2.36B |
| Revenue (ttm) | 485.47M |
| Net Income (ttm) | 47.08M |
| Shares Out | n/a |
| EPS (ttm) | 0.83 |
| PE Ratio | 50.10 |
| Forward PE | 19.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31 |
| Average Volume | 169 |
| Open | 53.14 |
| Previous Close | 52.79 |
| Day's Range | 53.14 - 54.95 |
| 52-Week Range | 29.68 - 54.95 |
| Beta | n/a |
| RSI | 67.19 |
| Earnings Date | Nov 4, 2025 |
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN... [Read more]
Financial Performance
In 2024, Supernus Pharmaceuticals's revenue was $661.82 million, an increase of 8.94% compared to the previous year's $607.52 million. Earnings were $73.87 million, an increase of 5512.84%.
Financial numbers in USD Financial StatementsNews
Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Piper San...
Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue?
Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Supernus Pharmaceuticals: Heading In The Right Direction
Supernus Pharmaceuticals to Participate in September Investor Conferences
ROCKVILLE, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Insider Decision: Frederick Hudson Offloads $315K Worth Of Supernus Pharmaceuticals Stock
Making a noteworthy insider sell on August 18, Frederick Hudson , Director at Supernus Pharmaceuticals (NASDAQ: SUPN), is reported in the latest SEC filing. What Happened: Hudson's decision to sell 7...
Supernus Pharmaceuticals Stock Scores RS Rating Upgrade
A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance.
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript
Supernus Pharmaceuticals GAAP EPS of $0.40 beats by $0.46, revenue of $165.5M beats by $11.42M
Supernus Announces Second Quarter 2025 Financial Results
ROCKVILLE, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Acquisition strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- t...
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting perio...
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sage ...
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma
Biogen Inc. (NASDAQ: BIIB) on Wednesday announced in a press release the topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for ...
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sage ...
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) on Monday agreed to acquire Sage Therapeutics, Inc. (NASDAQ: SAGE) for $12.00 per share in cash, or an aggregate of up to approximately $795 million. Th...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.
NEW YORK , June 16, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Sage Therapeutics, Inc. (NASDAQ: SAGE) and its board of directors concerning the propos...
S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June
U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 1% on Monday. The Dow traded up 0.80% to 42,536.72 while the NASDAQ climbed 1.51% to 19,699.21. The S&P 500 also rose,...
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Monday. Shares of Sage Therapeutics, Inc . (NASDAQ: SAGE) rose sharply during Monday's session after Supernus Pharmaceut...
Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal
Supernus to acquire Sage Therapeutics for $795 million, ... Full story available on Benzinga.com
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million
Supernus Pharmaceuticals agreed Monday to buy beleaguered biotech Sage Therapeutics in a deal worth up to $561 million.
Sage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know.
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal
Drugmaker Supernus Pharmaceuticals said on Monday it will acquire Sage Therapeutics , which makes treatments for neurological conditions, in a deal worth up to $795 million.
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
ROCKVILLE, Md. and CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced a definitive agreement ...
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extend...